Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 42
Filter
1.
Acta Obstet Gynecol Scand ; 100(11): 2066-2075, 2021 Nov.
Article in English | MEDLINE | ID: mdl-34480341

ABSTRACT

INTRODUCTION: Hereditary leiomyomatosis and renal cell cancer (HLRCC) constitute a tumor susceptibility syndrome caused by germline mutations in the fumarate hydratase (FH) gene. The most common features are leiomyomas of the uterus and the skin. The syndrome includes a predisposition to early-onset, aggressive renal cell cancer. It is important to identify women with HLRCC among other uterine leiomyoma patients in order to direct them to genetic counseling and to identify other affected family members. MATERIAL AND METHODS: We conducted a nationwide historical study to identify typical clinical characteristics, uterine leiomyoma morphology, and immunohistochemistry for diagnosing HLRCC. The study included 20 women with a known FH germline mutation and 77 women with sporadic uterine leiomyomas. The patient records of all women were reviewed to obtain clinical details regarding their leiomyomas. Uterine leiomyoma tissue specimens from 43 HLRCC-related leiomyomas and 42 sporadic leiomyomas were collected and prepared for histology analysis. A morphologic description was performed on hematoxylin & eosin-stained tissue slides, and immunohistochemical analysis was carried out for CD34, Bcl-2, and p53 stainings. RESULTS: The women with HLRCC were diagnosed with uterine leiomyomas at a young age compared with the sporadic leiomyoma group (mean 33.8 years vs. 45.4 years, P < 0.0001), and their leiomyomas occurred as multiples compared with the sporadic leiomyoma group (more than four tumors 88.9% vs. 30.8%, P < 0.0001). Congruently, these women underwent surgical treatment at younger age compared with the sporadic leiomyoma group (mean 37.3 years vs. 48.3 years, P < 0.0001). HLRCC leiomyomas had denser microvasculature highlighted by CD34 immunostaining when compared with the sporadic leiomyoma group (112.6 mean count/high-power field, SD 20.8 vs. 37.4 mean count/high-power field, SD 21.0 P < 0.0001) and stronger anti-apoptotic protein Bcl-2 immunostaining when compared with the sporadic leiomyoma group (weak 4.7%, moderate 44.2%, strong 51.2% vs. 26.2%, 52.4%, 21.4%, respectively, P = 0.003). No differences were observed in p53 staining. CONCLUSIONS: Women with HLRCC may be identified through the distinct clinical characteristics: symptomatic and numerous leioymyomas at young age, and morphologic features of FH-mutant leiomyomas, aided by Bcl-2 and CD34 immunohistochemistry. Further, distinguishing individuals with a germline FH mutation enables proper genetic counseling and regular renal monitoring.


Subject(s)
Leiomyomatosis/diagnosis , Neoplastic Syndromes, Hereditary/diagnosis , Skin Neoplasms/diagnosis , Uterine Neoplasms/diagnosis , Adult , Age Factors , Female , Germ-Line Mutation , Humans , Leiomyomatosis/genetics , Middle Aged , Neoplastic Syndromes, Hereditary/genetics , Skin Neoplasms/genetics , Syndrome , Uterine Neoplasms/genetics
2.
Arch Gynecol Obstet ; 302(4): 853-860, 2020 10.
Article in English | MEDLINE | ID: mdl-32653948

ABSTRACT

PURPOSE: To evaluate the performance of first trimester maternal serum glycosylated (Sambucus nigra lectin-reactive) fibronectin in prediction of gestational diabetes mellitus (GDM). METHODS: In this case-control study, first trimester maternal serum glycosylated fibronectin and fibronectin were measured in 19 women who consequently developed GDM and in 59 control women with normal pregnancy outcomes. Adiponectin was used as a reference protein to evaluate relation of glycoprotein to SNA-lectin-reactive assay format. Samples were taken during gestational weeks 9+6-11+6. Data concerning GDM was obtained from the National Institute for Health and Welfare, which records the pregnancy outcomes of all women in Finland. RESULTS: There was no difference in maternal serum glycosylated fibronectin concentrations between women with consequent GDM [447.5 µg/mL, interquartile range (IQR) 254.4-540.9 µg/mL] and control women (437.6 µg/mL, IQR 357.1-569.1 µg/mL). Maternal serum fibronectin levels were significantly lower in GDM group (224.2 µg/mL, IQR 156.8-270.6 µg/mL), compared to the control group (264.8 µg/mL, IQR 224.6-330.6 µg/mL, p < 0.01). There was no difference in assay formats for adiponectin. CONCLUSION: There was no association between first trimester maternal serum glycosylated (SNA-reactive) fibronectin and GDM.


Subject(s)
Diabetes, Gestational/blood , Fibronectins/blood , Adiponectin/blood , Adult , Biomarkers/blood , Case-Control Studies , Female , Fibronectins/metabolism , Finland , Glycation End Products, Advanced , Humans , Maternal Serum Screening Tests , Pregnancy , Pregnancy Outcome , Pregnancy Trimester, First/blood , Retrospective Studies , Sensitivity and Specificity
3.
J Matern Fetal Neonatal Med ; 32(9): 1454-1460, 2019 May.
Article in English | MEDLINE | ID: mdl-29157037

ABSTRACT

OBJECTIVE: To evaluate the performance of first-trimester measurement of fetal nuchal translucency (NT) in the detection of severe congenital heart defects (CHDs). METHODS: During the study period of 1 January 2008 - 31 December 2011, NT was measured in 31,144 women as a part of voluntary first-trimester screening program for Down's syndrome in Northern Finland. NT was measured by personnel trained on the job by the experienced staff. No certification or annual audits are required in Finland. However, the recommendation is that the examiner should perform 200 scans on average per year. Severe CHD was classified as a defect requiring surgery in the first year of life or a defect that led to the termination of the pregnancy. All severe CHDs diagnosed during the study period in Northern Finland could not be included in this study since all women did not participate in the first-trimester screening and some cases were missing important data. RESULTS: Fourteen (17.7%) out of 79 severe CHDs were found with NT cutoff of 3.5 mm. Amongst the 79 severe CHD cases, there were 17 chromosomal abnormalities. With NT cutoffs of 2.0 and 1.5 mm the detection rates would have increased to 25.3% (n = 20) and 46.8% (n = 37). Using a randomly selected control group of 762 women with normal pregnancy outcomes, false positive rates (FPRs) were calculated. For NT cutoffs of 1.5, 2.0 and 3.5 mm, the FPRs were, 18.5, 3.3 and 0.4%, respectively. CONCLUSIONS: A greater than 3.5 mm NT measurement in the first-trimester ultrasound is an indication to suspect a fetal heart defect but its sensitivity to detect severe CHD is poor. In our study, only 17.7% of severe CHDs would have been detected with an NT cutoff of 3.5 mm.


Subject(s)
Heart Defects, Congenital/diagnostic imaging , Nuchal Translucency Measurement , Adult , Case-Control Studies , Female , Finland/epidemiology , Humans , Mass Screening/statistics & numerical data , Pregnancy , Pregnancy Outcome/epidemiology , Pregnancy Trimester, First , Retrospective Studies , Sensitivity and Specificity , Severity of Illness Index
4.
J Matern Fetal Neonatal Med ; 32(19): 3272-3277, 2019 Oct.
Article in English | MEDLINE | ID: mdl-29683008

ABSTRACT

Objective: To evaluate the performance of first trimester biochemical markers, pregnancy-associated plasma protein-A (PAPP-A), free beta human chorionic gonadotropin (fß-hCG), and nuchal translucency (NT) in detection of severe congenital heart defects (CHDs). Methods: During the study period from 1 January 2008 to 31 December 2011, biochemical markers and NT were measured in 31,144 women as part of voluntary first trimester screening program for Down's syndrome in Northern Finland. Data for 71 severe CHD cases and 762 controls were obtained from the hospital records and from the National Medical Birth Register, which records the birth of all liveborn and stillborn infants, and from the National Register of Congenital Malformations that receives information about all the CHD cases diagnosed in Finland. Results: Both PAPP-A and fß-hCG multiple of median (MoM) values were decreased in all severe CHDs: 0.71 and 0.69 in ventricular septal defects (VSDs), 0.58 and 0.88 in tetralogy of Fallot cases (TOFs), 0.82 and 0.89 in hypoplastic left heart syndromes (HLHSs), and 0.88 and 0.96 in multiple defects, respectively. NT was increased in all study groups except of VSD group. ROC AUC was 0.72 for VSD when combining prior risk with PAPP-A and fß-hCG. Adding NT did not improve the detection rate. With normal NT but decreased (<0.5 MoM) PAPP-A and fß-hCG odds ratios for VSD and HLHS were 19.5 and 25.6, respectively. Conclusions: Maternal serum biochemistry improves the detection of CHDs compared to NT measurement only. In cases with normal NT measurement but low concentrations of both PAPP-A and fß-hCG, an alert for possible CHD, especially VSD, could be given with thorough examination of fetal heart in later ultrasound scans.


Subject(s)
Biomarkers/analysis , Heart Defects, Congenital/diagnosis , Maternal Serum Screening Tests/methods , Pregnancy Trimester, First/blood , Adult , Biomarkers/blood , Case-Control Studies , Chorionic Gonadotropin, beta Subunit, Human/blood , Female , Finland , Heart Defects, Congenital/blood , Humans , Predictive Value of Tests , Pregnancy , Pregnancy-Associated Plasma Protein-A/analysis , Pregnancy-Associated Plasma Protein-A/metabolism , Prenatal Diagnosis/methods , Young Adult
5.
Eur J Obstet Gynecol Reprod Biol ; 230: 32-35, 2018 Nov.
Article in English | MEDLINE | ID: mdl-30243226

ABSTRACT

OBJECTIVE: Maternal thrombophilia is a risk factor for adverse pregnancy outcomes. The aim of this study was to elucidate the controversial role of fetal and paternal thrombophilia in the development of severe placenta-mediated pregnancy complications. STUDY DESIGN: The study group comprised 126 mothers, 72 fetuses and 58 fathers. 111 mothers, 50 fetuses and 91 fathers acted as controls. 106 couples were selected to study the thrombophilias of paternal inheritance, 58 from the study group and 48 from the control group. The prevalence of factor V Leiden mutation, prothrombin G20210 A mutation and homozygous 10-methylenetetrahydrofolate reductase C677 T mutations were compared between the study and control groups to study whether maternal, fetal or paternal thrombophilias increase the risk of severe preeclampsia, intrauterine growth restriction, placental abruption and stillbirth. RESULTS: The total prevalence of fetal thrombophilic mutations was 8.3% in the study group and 14.0% in the control group. Paternal prevalence of thrombophilic mutations was 6.8% and 4.3%, respectively. There were no statistical differences between fetal or paternal thrombophilic mutations between the study and control groups. CONCLUSION: Fetal or paternal factor V Leiden mutation is not associated with severe placenta-mediated pregnancy complications.


Subject(s)
Activated Protein C Resistance/genetics , Fetal Diseases/genetics , Paternal Inheritance/genetics , Placenta Diseases/genetics , Pregnancy Complications, Hematologic/genetics , Abruptio Placentae/epidemiology , Abruptio Placentae/genetics , Activated Protein C Resistance/epidemiology , Adult , Case-Control Studies , Factor V/genetics , Female , Fetal Diseases/epidemiology , Fetal Growth Retardation/epidemiology , Fetal Growth Retardation/genetics , Humans , Male , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Mutation , Placenta Diseases/epidemiology , Pre-Eclampsia/epidemiology , Pre-Eclampsia/genetics , Pregnancy , Pregnancy Complications, Hematologic/epidemiology , Pregnancy Outcome , Prevalence , Prothrombin/genetics , Stillbirth/epidemiology , Stillbirth/genetics
6.
Metabolism ; 75: 6-15, 2017 10.
Article in English | MEDLINE | ID: mdl-28964327

ABSTRACT

OBJECTIVE: To develop a predictive risk model for early-onset pre-eclampsia (EO-PE) using maternal characteristics, combined screening markers, previously reported biomarkers for PE and mean arterial pressure (MAP). METHODS: This retrospective study was conducted at Oulu University hospital between 2006 and 2010. Maternal serum from first trimester combined screening was further analyzed for alpha fetoprotein (AFP), placental growth factor (PlGF), soluble tumor necrosis factor receptor-1 (sTNFR1), retinol binding protein-4 (RBP4), a disintegrin and metalloprotease-12 (ADAM12), soluble P-selectin (sP-selectin), follistatin like-3 (FSTL3), adiponectin, angiopoietin-2 (Ang-2) and sex hormone binding globulin (SHBG). First, the training sample set with 29 cases of EO-PE and 652 controls was developed to study whether these biomarkers separately or in combination with prior risk (maternal characteristics, first trimester pregnancy associated plasma protein-A (PAPP-A) and free beta human chorionic gonadotrophin (fß-hCG)) could be used to predict the development of EO-PE. Second, the developed risk models were validated with a test sample set of 42 EO-PE and 141 control subjects. For the test set MAP data was also available. RESULTS: Single marker statistically significant (ANOVA p<0.05) changes between control and EO-PE pregnancies were observed with AFP, RBP4 and sTNFR1 with both training and test sample sets. Based on the test sample set performances, the best detection rate, 47% for a 10% false positive rate, was achieved with PlGF and sTNFR1 added with prior risk and MAP. CONCLUSION: Based on our results, the best first trimester biomarkers to predict the subsequent EO-PE were AFP, PlGF, RBP4 and sTNFR1. The risk models that performed best for the prediction of EO-PE included prior risk, MAP, sTNFR1 and AFP or PlGF or RBP4.


Subject(s)
Arterial Pressure/physiology , Pre-Eclampsia/diagnosis , Predictive Value of Tests , Pregnancy Trimester, First/blood , Adult , Biomarkers/blood , Case-Control Studies , Early Diagnosis , Female , Humans , Membrane Proteins/blood , Pre-Eclampsia/blood , Pregnancy , Receptors, Tumor Necrosis Factor, Type I/blood , Retinol-Binding Proteins, Plasma/analysis , Retrospective Studies , alpha-Fetoproteins/analysis
7.
J Perinat Med ; 45(7): 869-877, 2017 Oct 26.
Article in English | MEDLINE | ID: mdl-28593875

ABSTRACT

OBJECTIVE: To evaluate placental gene expression in severe early- or late-onset preeclampsia with intrauterine growth restriction compared to controls. STUDY DESIGN: Chorionic villus sampling was conducted after cesarean section from the placentas of five women with early- or late-onset severe preeclampsia and five controls for each preeclampsia group. Microarray analysis was performed to identify gene expression differences between the groups. RESULTS: Pathway analysis showed over-representation of gene ontology (GO) biological process terms related to inflammatory and immune response pathways, platelet development, vascular development, female pregnancy and reproduction in early-onset preeclampsia. Pathways related to immunity, complement and coagulation cascade were overrepresented in the hypergeometric test for the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Ten genes (ABI3BP, C7, HLA-G, IL2RB, KRBOX1, LRRC15, METTL7B, MPP5, RFLNB and SLC20A) had a ≥±1 fold expression difference in severe early-onset preeclampsia group compared to early controls. There were 362 genes that had a ≥±1 fold expression difference in severe early-onset preeclampsia group compared to late-onset preeclampsia group including ABI3BP, C7, HLA-G and IL2RB. CONCLUSION: There are significant differences in placental gene expression between severe early- and late-onset preeclampsia when both are associated with intrauterine growth restriction. ABI3BP, C7, HLA-G and IL2RB might contribute to the development of early form of severe preeclampsia.


Subject(s)
Fetal Growth Retardation/metabolism , Placenta/metabolism , Pre-Eclampsia/metabolism , Adult , Case-Control Studies , Female , Gene Expression Profiling , Humans , Pregnancy , Young Adult
8.
J Ultrasound Med ; 35(12): 2675-2680, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27872421

ABSTRACT

OBJECTIVES: The purpose of this study was to evaluate pregnancies with isolated short fetal femur and humerus on second-trimester sonography. Short fetal long bones are known to be associated with aneuploidy and structural anomalies. In this study, we wanted to show the risk of adverse pregnancy outcomes in euploid and nonanomalous pregnancies. METHODS: Singleton pregnancies with short femur and humerus were included. Pregnancies with normal fetal bone lengths and age-matched mothers were selected as controls. RESULTS: The study group included 30 pregnancies with short fetal femur and humerus, and the control group included 60 normal pregnancies. The overall odds ratio for an adverse pregnancy outcome in the study group was 24.9. Preterm delivery occurred significantly more frequently (odds ratio, 20.8; P < .001), and one-third of pregnancies were complicated by preeclampsia. In the group with short long bones, the odds ratio for a pathologic umbilical Doppler flow pattern was 45.2 (P < .001), and birth weight was significantly lower (P < .001). Also, 3 (10.3%) stillbirths and 4 (13.3%) cases of early neonatal death were recorded in this group. These complications were not recorded in the control group. The risk of emergency cesarean delivery was significantly higher in the group with short long bones (odds ratio, 11.8; P < .001). CONCLUSIONS: The risk of adverse pregnancy outcomes is significant in euploid and nonanomalous pregnancies with isolated short long bones. Close follow-up is needed during pregnancy.


Subject(s)
Femur/diagnostic imaging , Humerus/diagnostic imaging , Pregnancy Outcome , Pregnancy Trimester, Second , Ultrasonography, Prenatal , Adult , Female , Femur/abnormalities , Femur/embryology , Humans , Humerus/abnormalities , Humerus/embryology , Pregnancy , Retrospective Studies
9.
Hum Reprod ; 31(12): 2689-2703, 2016 12.
Article in English | MEDLINE | ID: mdl-27733532

ABSTRACT

STUDY QUESTION: Are uterine fibroids associated with increased cardiovascular risk? SUMMARY ANSWER: This study reports an association between increased serum lipids and metabolic syndrome with an increased risk of uterine fibroids. WHAT IS KNOWN ALREADY: Recent studies suggest similarities in biological disease mechanisms and risk factors for fibroids and atherosclerosis: obesity, hypertension and abnormal serum lipids. These findings are awaiting confirmation that a population-based follow-up study could offer with extensive health examination data collection linked with a national hospital discharge register. STUDY DESIGN, SIZE, DURATION: The Northern Finland Birth Cohort (NFBC1966) is a population-based long-term follow-up study including all children with estimated date of delivery in 1966 in the Northern Finland area. The data were collected from national registries, postal questionnaires and clinical health examinations. The study population for this study comprised all females included in the NFBC1966 that underwent an extensive clinical health examination at age 46 years (n = 3635). PARTICIPANTS/MATERIALS, SETTING, METHODS: All females included in the NFBC1966 who were alive and traceable (n = 5118) were invited for the 46-year follow-up study; 3268 (63.9%) responded, returned the postal questionnaire and attended the clinical examination. Uterine fibroid cases were identified through the national hospital discharge register that has data on disease diagnoses based on WHO ICD-codes. Uterine fibroid codes, ICD-9: 218 and ICD-10: D25 were used for case identification. Self-reported fibroid cases were identified through the postal questionnaire. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 729 fibroid cases were identified, including 293 based on hospital discharge registries. With adjustment for BMI, parity, education and current use of exogenous hormones the risk of prevalent fibroids rose significantly for every 1 mmol/l increase in LDL (OR = 1.13, 95% CI: 1.02-1.26 for all cases) and triglycerides (OR = 1.27, 95% CI: 1.09-1.49 for all cases). Metabolic syndrome associated with hospital discharge-based fibroid diagnosis (OR = 1.48, 95% CI: 1.09-2.01). Additionally every 1 unit increase in waist-hip ratio associated with fibroids (OR = 1.32, 95% CI: 1.10-1.57). LIMITATIONS, REASONS FOR CAUTION: The case ascertainment may present some limitations. There was likely an under-identification of cases and misclassification of some cases as controls; this would have diluted the effects of reported associations. The data analysed were cross-sectional and therefore cause and effect for the associations observed cannot be distinguished. WIDER IMPLICATIONS OF THE FINDINGS: Increased serum lipids and metabolic syndrome are associated with increased risk of uterine fibroids. Along with central obesity these findings add to an increased risk for cardiovascular disease among women with fibroids. These observations may suggest that there are shared predisposing factors underlying both uterine fibroids and adverse metabolic and cardiac disease risk, or that metabolic factors have a role in biological mechanisms underlying fibroid development. STUDY FUNDING/COMPETING INTERESTS: This study was supported by the Academy of Finland, University Hospital Oulu, University of Oulu, Finland, Northern Finland Health Care Foundation, Duodecim Foundation, ERDF European Regional Development Fund-Well-being and health: Research in the Northern Finland Birth Cohort 1966. The authors declare no conflict of interest.


Subject(s)
Cardiovascular Diseases/etiology , Leiomyoma/complications , Lipids/blood , Metabolic Syndrome/complications , Uterine Neoplasms/complications , Cardiovascular Diseases/blood , Cross-Sectional Studies , Female , Finland/epidemiology , Follow-Up Studies , Humans , Leiomyoma/blood , Leiomyoma/epidemiology , Metabolic Syndrome/blood , Middle Aged , Prevalence , Risk Factors , Uterine Neoplasms/blood , Waist-Hip Ratio
10.
Prenat Diagn ; 36(2): 163-9, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26697810

ABSTRACT

OBJECTIVE: The objective of this article is to estimate whether the maternal serum levels of A disintegrin and metalloprotease domain 12 (ADAM12-s), pregnancy-associated plasma protein-A (PAPP-A), and free beta human chorionic gonadotrophin (fß-hCG) are altered in assisted reproduction techniques (ART) pregnancies. METHOD: A retrospective cohort study with a control group was performed. Two hundred eighty-three ART pregnancies and 1008 controls were studied. The patients were divided into groups according to the type of conception: (1) controls, (2) fresh embryo transfer (ET) following controlled ovarian stimulation (COH) and in vitro fertilization (IVF), (3) fresh ET following COH and intracytoplasmic sperm injection (ICSI), (4) frozen ET during natural menstrual cycle (NC-FET), and (5) frozen ET using hormone replacement therapy. The cases and controls were matched for gestational and maternal age and for the storage time of the samples. RESULTS: The ADAM12-s levels were statistically significantly higher in the entire ART group, IVF and ICSI groups, and NC-FET group when compared with those in the controls. The PAPP-A levels were decreased only in the ICSI group compared with those in the controls. fß-hCG levels were not altered in assisted pregnancies. The ADAM12-s levels tended to increase with advanced gestational age. ADAM12-s levels were correlated with PAPP-A and fß-hCG levels in several subgroups of ART pregnancies. CONCLUSION: ADAM12-s and PAPP-A levels are altered in several subgroups of ART pregnancies. Larger studies are required to confirm these findings.


Subject(s)
ADAM Proteins/metabolism , Membrane Proteins/metabolism , Pregnancy-Associated Plasma Protein-A/metabolism , Reproductive Techniques, Assisted , ADAM12 Protein , Adolescent , Adult , Case-Control Studies , Chorionic Gonadotropin, beta Subunit, Human/metabolism , Cryopreservation , Embryo Transfer , Female , Fertilization in Vitro , Humans , Maternal Age , Middle Aged , Ovulation Induction , Pregnancy , Pregnancy Trimester, First , Retrospective Studies , Sperm Injections, Intracytoplasmic , Young Adult
11.
Rev Diabet Stud ; 13(4): 236-245, 2016.
Article in English | MEDLINE | ID: mdl-28278310

ABSTRACT

BACKGROUND: Current screening methods for gestational diabetes mellitus (GDM) are insufficient in detecting the risk of GDM in the first trimester of the pregnancy. Recent metabolomic studies have detected altered amino acid and acylcarnitine concentrations in type 2 diabetes (T2D). Because of the similarities between T2D and GDM, the determination of these metabolites may be useful in early screening for GDM. AIM: To evaluate the association between GDM and first-trimester maternal serum concentrations of ten amino acids and 31 acylcarnitines. METHODS: This retrospective case-control study included data from pregnant women screened at Oulu University Hospital between 1.1.2008 and 31.12.2011. A total of 31,146 women participated voluntarily in a first-trimester combined screening (for chromosomal abnormalities). The study population included 69 women who developed GDM during pregnancy and 295 women without diabetes before or after pregnancy. The serum concentrations of ten amino acids and 31 acylcarnitines were analyzed from frozen serum samples taken in the first-trimester screening. Multiple of median (MoM) values were compared between the two groups. RESULTS: In the GDM group, serum levels of arginine were significantly higher (1.13 MoM vs. 0.97 MoM), and those of glycine (0.93 MoM vs. 1.03 MoM) and 3-hydroxy-isovalerylcarnitine (0.86 MoM vs. 1.03 MoM) significantly lower compared to the control group (all p < 0.01). In each case, arginine, glycine, and 3-hydroxy-isovaleryl-carnitine would have detected 46%, 32%, and 39% of GDM cases, with a false-positive rate of 20%. Combining these three metabolites with the first-trimester serum marker pregnancy-associated plasma protein A (PAPP-A) and prior risk (age, BMI, and smoking) achieved a detection rate of 72%. CONCLUSION: There are significant differences in the serum levels of arginine, glycine, and 3-hydroxy-isovalerylcarnitine between controls and women who subsequently develop GDM. These differences were already existent in the first trimester of the pregnancy. The use of metabolites in combination with prior risk and first-trimester PAPP-A represents a reliable method to identify women at risk of GDM.


Subject(s)
Arginine/blood , Carnitine/analogs & derivatives , Diabetes, Gestational/diagnosis , Down-Regulation , Glycine/blood , Up-Regulation , Adult , Biomarkers/blood , Carnitine/blood , Case-Control Studies , Diabetes, Gestational/blood , Diabetes, Gestational/epidemiology , Female , Finland/epidemiology , Hospitals, University , Humans , Maternal Serum Screening Tests , Predictive Value of Tests , Pregnancy , Pregnancy Trimester, First , Retrospective Studies , Risk , Sensitivity and Specificity
12.
Article in English | MEDLINE | ID: mdl-26106266

ABSTRACT

OBJECTIVE: To evaluate the efficacy of first-trimester markers-pregnancy-associated plasma protein A (PAPPA), free human chorionic gonadotropin ß (fhCGß), alpha-fetoprotein (AFP), placental growth factor (PlGF), and soluble tumor necrosis factor receptor-1 (sTNFR1) together with maternal characteristics (MC) for prediction of early-onset preeclampsia (EOPE). METHODS: During 2005-2010, the abovementioned biomarkers were analyzed with logistic regression analysis in 64 EOPE and 752 control subjects to determine whether these biomarkers separately and in combination with MC would predict development of EOPE. RESULTS: PAPPA, fhCGß, and PlGF levels were lower, whereas AFP and sTNFR1 levels were higher in mothers with EOPE compared to controls. The combination of all markers with MC (age, weight, and smoking status) detected 48% of the mothers with EOPE, with a 10% false-positive rate (FPR). CONCLUSIONS: First-trimester maternal serum levels of PAPPA, fhCGß, AFP, PlGF, and sTNFR1, together with MC, are predictive of development of subsequent EOPE. These markers, along with MC, form a suitable panel for predicting EOPE.

13.
Metabolism ; 64(4): 521-6, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25633269

ABSTRACT

OBJECTIVE: In a retrospective case-control study, we examined the levels of placental retinol-binding protein 4 (RBP4) and pregnancy-associated placental protein A (PAPP-A) in first-trimester maternal serum samples as well as maternal characteristics to predict early-onset and severe pre-eclampsia. METHODS: In this retrospective case-control study, we identified females who delivered a singleton pregnancy on or after 24 weeks' gestation from 2003 to 2010 at Oulu University Hospital and had a retrospective first trimester trisomy screening, including serum PAPP-A measurement. Within this cohort, we identified 65 females who experienced early onset pre-eclampsia (EO-PE) and 742 controls who had uncomplicated deliveries. Retrospectively, we thawed all previously collected serum samples to measure placental retinol binding protein 4 (RBP4). PAPP-A and RBP4 were measured using automatic immunoassay systems and converted to multiples of the median (MoMs). Logistic regression analysis was performed to determine whether these biomarkers separately and in combination with maternal characteristics (maternal age, weight and smoking status) can be used to predict the development of early onset pre-eclampsia. RESULTS: The expected log(10) PAPP-A concentration and the expected log(10) RBP4 concentration in the control group were both affected by maternal weight and smoking status. The expected log(10) PAPP-A concentration was also affected by gestational age (GA). RBP4 levels in first-trimester serum were significantly higher in females who subsequently developed EO-PE outcome compared to those with normal pregnancy outcome (1.14 vs. 1.01 MoMs, p<0.0001). Maternal serum PAPP-A levels from the same pregnancy period were significantly lower in the EO-PE group compared to controls (0.80 vs. 1.05 MoMs, p=0.005). The risk model including maternal characteristics with PAPP-A log(10) MoM and RBP4 log(10) MoM had the best EO-PE prediction ability. It detected 34% (23%-46%) of females with subsequent EO-PE with a 10% false positive rate. CONCLUSION: This study showed that first-trimester maternal serum RBP4 was significantly increased and that PAPP-A decreased in pregnancies that ended in EO-PE compared to normal pregnancies. Thus, these markers may be useful members in a panel of markers for the early detection of early-onset and severe pre-eclampsia.


Subject(s)
Pre-Eclampsia/diagnosis , Pregnancy Trimester, First/blood , Pregnancy-Associated Plasma Protein-A/metabolism , Retinol-Binding Proteins, Plasma/metabolism , Adult , Age of Onset , Biomarkers/blood , Case-Control Studies , Early Diagnosis , Female , Gestational Age , Humans , Pre-Eclampsia/blood , Pre-Eclampsia/epidemiology , Pregnancy , Prognosis , Severity of Illness Index
14.
Article in English | MEDLINE | ID: mdl-25140118

ABSTRACT

OBJECTIVE: To evaluate the efficacy of first trimester combined screening for Down's syndrome in Northern Finland during the first 10 years of practice. METHODS: During 1 January 2002 to 31 December 2011, 47,896 women participated voluntarily in combined screening during first trimester. The risk cutoff was 1:250. The study period was divided into two time periods; 2002-2006 and 2007-2011. RESULTS: During the first half of the study period, the detection rate (DR) was 77.3% with a 4.9% false-positive rate (FPR). During the latter half, the DR was 77.1% with a 2.8% FPR. CONCLUSIONS: An important issue is the number of invasive procedures needed to detect one case of Down's syndrome. The screening performance improved markedly in the latter five years period since the FPR lowered from 4.9% to 2.8% and the number of invasive procedures needed to detect one case of Down's syndrome lowered from 15 to 11.

16.
Acta Obstet Gynecol Scand ; 92(7): 769-74, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23369035

ABSTRACT

OBJECTIVE: To compare the efficacy of fetal nuchal translucency screening, maternal serum screening and combined screening for Down syndrome. DESIGN: A prospective study. SETTING: University hospital and its public health care district in Northern Finland. POPULATION: A total of 35,314 women participated in the first-trimester screening for Down syndrome within the public healthcare system in 2002-08. There were 95 pregnancies involving Down syndrome. Serum samples were obtained from 35,314 women, nuchal translucency was measured in 27,144 pregnancies and full combined screening was performed in those pregnancies, including 76 involving Down syndrome. METHODS: The adjusted estimated risk for Down syndrome was calculated using the Perkin Elmer AutoDELFIA® time-resolved fluoroimmunoassay kit for the measurement of pregnancy-associated plasma protein-A and free ß-human chorionic gonadotropin. Nuchal translucency was measured by trained personnel in a university or district hospital. Risk cut-off figures 1:250 and 1:300 at term were used. MAIN OUTCOME MEASURES: Differences in detection rate, false-positive rate, positive and negative predictive values between nuchal translucency screening, serum screening and combined screening. RESULTS: Using the risk cut-off figure 1:250, the detection rates for serum screening, nuchal translucency screening and combined screening were 64.2, 64.5 and 72.4%, respectively and the false-positive rates were 7.8, 4.4 and 4.0%, respectively. CONCLUSIONS: Combined screening is the method of choice for Down syndrome screening in Finland.


Subject(s)
Chorionic Gonadotropin, beta Subunit, Human/blood , Down Syndrome/diagnosis , Maternal Serum Screening Tests , Nuchal Translucency Measurement , Pregnancy Trimester, First , Pregnancy-Associated Plasma Protein-A/metabolism , Adult , Biomarkers/blood , False Positive Reactions , Female , Finland , Humans , Predictive Value of Tests , Pregnancy , Pregnancy Trimester, First/blood , Prospective Studies , Risk Assessment
17.
J Eval Clin Pract ; 19(2): 324-6, 2013 Apr.
Article in English | MEDLINE | ID: mdl-22458815

ABSTRACT

OBJECTIVES: We evaluated the performance of first trimester screening for Down syndrome in women less than 35 years of age (study group) and in women aged 35 years or more (control group) in an unselected low-risk population. METHODS: The study group comprised a total of 63,945 women who participated in the first trimester combined screening in public health care in Finland during the study period of 1 May 2002 to 31 December 2008. Women at the age of 35 or more (n = 13,004) were controls. Prevalence of Down syndrome, detection rate, false positive rate and number of invasive procedures needed to detect a single case of Down syndrome were analyzed in both groups. RESULTS: The overall prevalence of Down syndrome (n = 73) in the study group was 1:876. The number of detected cases was 54. The detection rate was 74.0% with a false positive rate of 2.8%. Number of invasive procedures needed to detect a single case of Down syndrome was 33. In the control group, the detection rate was 87.0% with a false positive rate of 11.9%. The number of invasive procedures needed to detect a single case of Down syndrome was 15. The differences in detection rate and false positive rate were significant, P < 0.012, P < 0.001, respectively. CONCLUSION: The overall detection rate given for the entire population is an overestimate for a woman younger than the age of 35, which should be taken into consideration when counselling women of that age.


Subject(s)
Down Syndrome/diagnosis , Maternal Age , Pregnancy Trimester, First , Adult , Down Syndrome/epidemiology , False Positive Reactions , Female , Finland/epidemiology , Humans , Mass Screening , Pregnancy , Prenatal Diagnosis/methods , Prenatal Diagnosis/statistics & numerical data
18.
Hum Reprod ; 27(6): 1865-9, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22473397

ABSTRACT

Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a tumor predisposition syndrome characterized by cutaneous and uterine leiomyomas and renal cell cancer. HLRCC is caused by heterozygous germline mutations in the fumarate hydratase (FH) gene. A Finnish family with nine closely related women with uterine leiomyomas was detected by an alert gynecologist. No cutaneous or renal cell tumors were reported in the family when it was referred to genetic analyses. Samples were available from seven patients, and a novel germline FH mutation was detected in five of them. Mutation carriers were symptomatic, had multiple tumors and were diagnosed at an early age. This study emphasizes the importance of considering FH mutation screening when gynecologists encounter families with multiple severe uterine leiomyoma cases. Due to possibility of phenocopies more than one patient should be tested. Early mutation detection allows regular screening of the mutation carriers and enables early detection of possible highly aggressive renal tumors. It may also affect family planning as multiple myomas at early age may significantly reduce fertility.


Subject(s)
Fumarate Hydratase/genetics , Germ-Line Mutation/genetics , Leiomyoma/genetics , Uterine Neoplasms/genetics , Adult , DNA Mutational Analysis , Female , Finland , Genetic Carrier Screening , Genetic Predisposition to Disease , Humans , Kidney Neoplasms/genetics , Leiomyomatosis/genetics , Middle Aged , Neoplastic Syndromes, Hereditary/genetics , Pedigree , Skin Neoplasms
19.
Prenat Diagn ; 32(2): 160-7, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22418960

ABSTRACT

OBJECTIVE: Earlier studies have shown that maternal hormone secretion during late first or second trimester may be affected by gravidity. We examined the luteoplacental hormone secretion during 5-11 weeks of gestation in relation to gravidity. METHOD: Forty-one naturally conceived pregnancies underwent weekly assessment of serum human chorionic gonadotrophin, progesterone and 17-OH progesterone, estradiol, testosterone, and pregnancy-associated plasma protein A levels. In addition, the volume and the vasculature of the dominant ovary with corpus luteum were assessed with the use of a 3-dimensional power Doppler ultrasonography. Areas under the curve for hormonal and ultrasonographic parameters were calculated. RESULTS: Twenty-two out of the 41 women were pregnant for the first time. All the pregnancies were uncomplicated and resulted in term deliveries of appropriately grown newborns. During pregnancy weeks 5-11, the secretion (area under the curve) of human chorionic gonadotrophin (6.54 ± 0.03 vs 6.39 ± 0.05, p = 0.010), progesterone (3.49 ± 0.02 vs 3.36 ± 0.03, p = 0.003), and 17-OH progesterone (2.73 ± 0.03 vs 2.62 ± 0.03, p = 0.013) were higher in primigravid than in multigravid women. No other differences were detected between primigravid and multigravid women. CONCLUSION: The placental function already differs between primigravid and multigravid women during the first weeks of pregnancy, which reflects the corpus luteal function.


Subject(s)
Fetus/physiology , Parity/physiology , Placental Hormones/blood , Pregnancy Trimester, First/blood , Sex , Adult , Birth Weight , Corpus Luteum/metabolism , Female , Humans , Infant, Newborn , Male , Ovary/blood supply , Pregnancy , Pregnancy Outcome , Sex Determination Analysis , Ultrasonography, Doppler , Ultrasonography, Prenatal , Young Adult
20.
J Matern Fetal Neonatal Med ; 25(6): 822-5, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22309076

ABSTRACT

OBJECTIVE: To investigate first trimester levels of ADAM12 in trisomy 18 and 13 pregnancies and whether incorporating ADAM12 in the LifeCycle™ risk calculation program of trisomy 18 and trisomy 13 screenings can improve the detection rates of trisomies 18 and 13. METHODS: ADAM12 was incorporated in the LifeCycle™ risk calculation program. A specific algorithm with cut-off of 1:200 for screening of trisomies 18 and 13 was employed. Detection rates for trisomies 18 and 13 were calculated. RESULTS: There was a significant difference in ADAM12 levels between trisomy 18 pregnancies and controls during the gestation weeks 9 + 0 - 10 + 6, but not thereafter. In trisomy 13 pregnancies there was no difference in weeks 9 + 0 - 10 + 6, but there was in 11 + 0 - 12 + 6. The specific algorithms for trisomies 18 and 13 combined with algorithm for trisomy 21 yielded detection rates of 73.7% and 66.7%, respectively. The combined false positive rate was 4.6%. Adding ADAM12, the detection rate for trisomy 18 was the same, at 73.7% and for trisomy 13, at 66.7%. CONCLUSION: ADAM12 did not improve the detection rate.


Subject(s)
ADAM Proteins/analysis , Chromosomes, Human, Pair 13 , Chromosomes, Human, Pair 18 , Membrane Proteins/analysis , Pregnancy Trimester, First , Prenatal Diagnosis/statistics & numerical data , Trisomy/diagnosis , ADAM Proteins/blood , ADAM12 Protein , Adult , Chromosomes, Human, Pair 13/genetics , Chromosomes, Human, Pair 18/genetics , Female , Humans , Mass Screening/methods , Mass Screening/statistics & numerical data , Membrane Proteins/blood , Pregnancy , Pregnancy Complications/diagnosis , Pregnancy Complications/epidemiology , Pregnancy Complications/etiology , Pregnancy Complications/genetics , Pregnancy Trimester, First/blood , Pregnancy Trimester, First/genetics , Prenatal Diagnosis/methods , Prenatal Diagnosis/standards , Risk Assessment , Trisomy/genetics , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...